Response-oriented individualized induction therapy with six drugs followed by four courses of intensive consolidation, 1 year maintenance and intensification therapy: The ALL90 study of the Japan Adult Leukemia Study Group

T. Ueda, S. Miyawaki, N. Asou, Y. Kuraishi, A. Hiraoka, K. Kuriyama, S. Minami, T. Ohshima, T. Ino, J. Tamura, A. Kanamaru, K. Nishikawa, M. Tanimoto, H. Oh, K. Saito, K. Nagata, T. Naoe, O. Yamada, Y. Urasaki, T. SakuraR. Ohno

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Adult patients with acute lymphoblastic leukemia (ALL) were treated according to the ALL90 study, the second prospective study for ALL of the Japan Adult Leukemia Study Group (JALSG). Its characteristics included nisolone, cyclophosphamide and 1-asparaginase), and a prospective comparison between allogeneic bone marrow transplantation (allo-BMT) and chemotherapy alone in patients below 45 years of age. The protocol consisted of one or two courses of induction, four courses of consolidation, and three courses of intensification including 12 month maintenance and six times of central nervous system (CNS) prophylaxis. Of 180 evaluable patients (median age, 43), 125 (69%) achieved complete remission (CR). Predicted overall survival (OAS), event-free survival and disease-free survival (DFS) were 15, 10 and 14%, respectively at the median follow-up period of 62 months. No specific toxicities were observed. Leukocytes <30 000/μl, normal karyotype, and blasts <10% in bone marrow at day 15 of induction therapy were significantly favorable prognostic factors for the achievement of CR, DFS and OAS by univariate analysis. Multivariate analysis showed leukocytes <30 000/μl and blasts <10% on day 15 was a significant factor for the achievement of CR, DFS and OAS. Ph-chromosome was found in 28% (36/130) of patients examined and was one of the worst prognostic factors. All Ph positive patients were predicted to die within 600 days. Allo-BMT was not significantly superior to chemotherapy with respect to DFS (P = 0.226). The overall results were inferior to those of the former ALL87 protocol. As reasons, the older median age of 43 years old (vs. 38 years old) and lower dose intensity, especially of l-asparaginase, etc. were suggested. However, patients with good prognostic factors (leukocyte <30 000/μl and age <30 years old) showed better survival than others (P <0.0001), and the result was similar to that of older children, the high risk group of childhood ALL, suggesting that ALL could be a disease of single entity, showing higher resistance to chemotherapy as patients become older.

Original languageEnglish
Pages (from-to)279-289
Number of pages11
JournalInternational Journal of Hematology
Volume68
Issue number3
Publication statusPublished - Oct 1998
Externally publishedYes

Fingerprint

Japan
Leukemia
Maintenance
Disease-Free Survival
Pharmaceutical Preparations
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Asparaginase
Leukocytes
Drug Therapy
Therapeutics
Survival
Homologous Transplantation
Survival Analysis
Bone Marrow Transplantation
Karyotype
Cyclophosphamide
Multivariate Analysis
Central Nervous System
Chromosomes
Bone Marrow

Keywords

  • Acute lymphoblastic leukemia
  • Age
  • Japan Adult Leukemia Study Group (JALSG)
  • Prognostic factor
  • Response-oriented individualized chemotherapy

ASJC Scopus subject areas

  • Hematology

Cite this

Response-oriented individualized induction therapy with six drugs followed by four courses of intensive consolidation, 1 year maintenance and intensification therapy : The ALL90 study of the Japan Adult Leukemia Study Group. / Ueda, T.; Miyawaki, S.; Asou, N.; Kuraishi, Y.; Hiraoka, A.; Kuriyama, K.; Minami, S.; Ohshima, T.; Ino, T.; Tamura, J.; Kanamaru, A.; Nishikawa, K.; Tanimoto, M.; Oh, H.; Saito, K.; Nagata, K.; Naoe, T.; Yamada, O.; Urasaki, Y.; Sakura, T.; Ohno, R.

In: International Journal of Hematology, Vol. 68, No. 3, 10.1998, p. 279-289.

Research output: Contribution to journalArticle

Ueda, T, Miyawaki, S, Asou, N, Kuraishi, Y, Hiraoka, A, Kuriyama, K, Minami, S, Ohshima, T, Ino, T, Tamura, J, Kanamaru, A, Nishikawa, K, Tanimoto, M, Oh, H, Saito, K, Nagata, K, Naoe, T, Yamada, O, Urasaki, Y, Sakura, T & Ohno, R 1998, 'Response-oriented individualized induction therapy with six drugs followed by four courses of intensive consolidation, 1 year maintenance and intensification therapy: The ALL90 study of the Japan Adult Leukemia Study Group', International Journal of Hematology, vol. 68, no. 3, pp. 279-289.
Ueda, T. ; Miyawaki, S. ; Asou, N. ; Kuraishi, Y. ; Hiraoka, A. ; Kuriyama, K. ; Minami, S. ; Ohshima, T. ; Ino, T. ; Tamura, J. ; Kanamaru, A. ; Nishikawa, K. ; Tanimoto, M. ; Oh, H. ; Saito, K. ; Nagata, K. ; Naoe, T. ; Yamada, O. ; Urasaki, Y. ; Sakura, T. ; Ohno, R. / Response-oriented individualized induction therapy with six drugs followed by four courses of intensive consolidation, 1 year maintenance and intensification therapy : The ALL90 study of the Japan Adult Leukemia Study Group. In: International Journal of Hematology. 1998 ; Vol. 68, No. 3. pp. 279-289.
@article{2d388dfb25914717900ade07aa2c2267,
title = "Response-oriented individualized induction therapy with six drugs followed by four courses of intensive consolidation, 1 year maintenance and intensification therapy: The ALL90 study of the Japan Adult Leukemia Study Group",
abstract = "Adult patients with acute lymphoblastic leukemia (ALL) were treated according to the ALL90 study, the second prospective study for ALL of the Japan Adult Leukemia Study Group (JALSG). Its characteristics included nisolone, cyclophosphamide and 1-asparaginase), and a prospective comparison between allogeneic bone marrow transplantation (allo-BMT) and chemotherapy alone in patients below 45 years of age. The protocol consisted of one or two courses of induction, four courses of consolidation, and three courses of intensification including 12 month maintenance and six times of central nervous system (CNS) prophylaxis. Of 180 evaluable patients (median age, 43), 125 (69{\%}) achieved complete remission (CR). Predicted overall survival (OAS), event-free survival and disease-free survival (DFS) were 15, 10 and 14{\%}, respectively at the median follow-up period of 62 months. No specific toxicities were observed. Leukocytes <30 000/μl, normal karyotype, and blasts <10{\%} in bone marrow at day 15 of induction therapy were significantly favorable prognostic factors for the achievement of CR, DFS and OAS by univariate analysis. Multivariate analysis showed leukocytes <30 000/μl and blasts <10{\%} on day 15 was a significant factor for the achievement of CR, DFS and OAS. Ph-chromosome was found in 28{\%} (36/130) of patients examined and was one of the worst prognostic factors. All Ph positive patients were predicted to die within 600 days. Allo-BMT was not significantly superior to chemotherapy with respect to DFS (P = 0.226). The overall results were inferior to those of the former ALL87 protocol. As reasons, the older median age of 43 years old (vs. 38 years old) and lower dose intensity, especially of l-asparaginase, etc. were suggested. However, patients with good prognostic factors (leukocyte <30 000/μl and age <30 years old) showed better survival than others (P <0.0001), and the result was similar to that of older children, the high risk group of childhood ALL, suggesting that ALL could be a disease of single entity, showing higher resistance to chemotherapy as patients become older.",
keywords = "Acute lymphoblastic leukemia, Age, Japan Adult Leukemia Study Group (JALSG), Prognostic factor, Response-oriented individualized chemotherapy",
author = "T. Ueda and S. Miyawaki and N. Asou and Y. Kuraishi and A. Hiraoka and K. Kuriyama and S. Minami and T. Ohshima and T. Ino and J. Tamura and A. Kanamaru and K. Nishikawa and M. Tanimoto and H. Oh and K. Saito and K. Nagata and T. Naoe and O. Yamada and Y. Urasaki and T. Sakura and R. Ohno",
year = "1998",
month = "10",
language = "English",
volume = "68",
pages = "279--289",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Response-oriented individualized induction therapy with six drugs followed by four courses of intensive consolidation, 1 year maintenance and intensification therapy

T2 - The ALL90 study of the Japan Adult Leukemia Study Group

AU - Ueda, T.

AU - Miyawaki, S.

AU - Asou, N.

AU - Kuraishi, Y.

AU - Hiraoka, A.

AU - Kuriyama, K.

AU - Minami, S.

AU - Ohshima, T.

AU - Ino, T.

AU - Tamura, J.

AU - Kanamaru, A.

AU - Nishikawa, K.

AU - Tanimoto, M.

AU - Oh, H.

AU - Saito, K.

AU - Nagata, K.

AU - Naoe, T.

AU - Yamada, O.

AU - Urasaki, Y.

AU - Sakura, T.

AU - Ohno, R.

PY - 1998/10

Y1 - 1998/10

N2 - Adult patients with acute lymphoblastic leukemia (ALL) were treated according to the ALL90 study, the second prospective study for ALL of the Japan Adult Leukemia Study Group (JALSG). Its characteristics included nisolone, cyclophosphamide and 1-asparaginase), and a prospective comparison between allogeneic bone marrow transplantation (allo-BMT) and chemotherapy alone in patients below 45 years of age. The protocol consisted of one or two courses of induction, four courses of consolidation, and three courses of intensification including 12 month maintenance and six times of central nervous system (CNS) prophylaxis. Of 180 evaluable patients (median age, 43), 125 (69%) achieved complete remission (CR). Predicted overall survival (OAS), event-free survival and disease-free survival (DFS) were 15, 10 and 14%, respectively at the median follow-up period of 62 months. No specific toxicities were observed. Leukocytes <30 000/μl, normal karyotype, and blasts <10% in bone marrow at day 15 of induction therapy were significantly favorable prognostic factors for the achievement of CR, DFS and OAS by univariate analysis. Multivariate analysis showed leukocytes <30 000/μl and blasts <10% on day 15 was a significant factor for the achievement of CR, DFS and OAS. Ph-chromosome was found in 28% (36/130) of patients examined and was one of the worst prognostic factors. All Ph positive patients were predicted to die within 600 days. Allo-BMT was not significantly superior to chemotherapy with respect to DFS (P = 0.226). The overall results were inferior to those of the former ALL87 protocol. As reasons, the older median age of 43 years old (vs. 38 years old) and lower dose intensity, especially of l-asparaginase, etc. were suggested. However, patients with good prognostic factors (leukocyte <30 000/μl and age <30 years old) showed better survival than others (P <0.0001), and the result was similar to that of older children, the high risk group of childhood ALL, suggesting that ALL could be a disease of single entity, showing higher resistance to chemotherapy as patients become older.

AB - Adult patients with acute lymphoblastic leukemia (ALL) were treated according to the ALL90 study, the second prospective study for ALL of the Japan Adult Leukemia Study Group (JALSG). Its characteristics included nisolone, cyclophosphamide and 1-asparaginase), and a prospective comparison between allogeneic bone marrow transplantation (allo-BMT) and chemotherapy alone in patients below 45 years of age. The protocol consisted of one or two courses of induction, four courses of consolidation, and three courses of intensification including 12 month maintenance and six times of central nervous system (CNS) prophylaxis. Of 180 evaluable patients (median age, 43), 125 (69%) achieved complete remission (CR). Predicted overall survival (OAS), event-free survival and disease-free survival (DFS) were 15, 10 and 14%, respectively at the median follow-up period of 62 months. No specific toxicities were observed. Leukocytes <30 000/μl, normal karyotype, and blasts <10% in bone marrow at day 15 of induction therapy were significantly favorable prognostic factors for the achievement of CR, DFS and OAS by univariate analysis. Multivariate analysis showed leukocytes <30 000/μl and blasts <10% on day 15 was a significant factor for the achievement of CR, DFS and OAS. Ph-chromosome was found in 28% (36/130) of patients examined and was one of the worst prognostic factors. All Ph positive patients were predicted to die within 600 days. Allo-BMT was not significantly superior to chemotherapy with respect to DFS (P = 0.226). The overall results were inferior to those of the former ALL87 protocol. As reasons, the older median age of 43 years old (vs. 38 years old) and lower dose intensity, especially of l-asparaginase, etc. were suggested. However, patients with good prognostic factors (leukocyte <30 000/μl and age <30 years old) showed better survival than others (P <0.0001), and the result was similar to that of older children, the high risk group of childhood ALL, suggesting that ALL could be a disease of single entity, showing higher resistance to chemotherapy as patients become older.

KW - Acute lymphoblastic leukemia

KW - Age

KW - Japan Adult Leukemia Study Group (JALSG)

KW - Prognostic factor

KW - Response-oriented individualized chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=0031723582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031723582&partnerID=8YFLogxK

M3 - Article

C2 - 9846012

AN - SCOPUS:0031723582

VL - 68

SP - 279

EP - 289

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 3

ER -